SCHEMBL18078640

SCHEMBL18078640

CN(C)CCCC(=O)Nc1cccc(Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 7/20 0.68
▸ CDK7 P50613 11/20 0.66
▸ CCNH P51946 10/20 0.66
▸ CDK1 P06493 3/20 0.66
▸ CDK5 Q00535 3/20 0.66
▸ CDK2 P24941 2/20 0.66
▸ CDK9 P50750 2/20 0.66
▸ MNAT1 P51948 2/20 0.66
▸ CDK8 P49336 1/20 0.66
▸ CDK13 Q14004 2/20 0.65
▸ CDK12 Q9NYV4 2/20 0.65
▸ CDK5R1 Q15078 2/20 0.65
▸ MAP3K11 Q16584 2/20 0.65
▸ CCNT1 O60563 1/20 0.65
▸ CCNK O75909 1/20 0.65
▸ CCNB1 P14635 1/20 0.65
▸ CCNA2 P20248 1/20 0.65
▸ MAPK8 P45983 1/20 0.65
▸ MAPK9 P45984 1/20 0.65
▸ KDR P35968 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29855866 0.94 CDK7 (0.75) EGFRCDK7CCNHCDK1CDK5
SCHEMBL20416128 0.94 CDK7 (0.65) EGFRCDK7CCNHCDK1CDK5
SCHEMBL18078648 0.89 EGFR (0.69) EGFRCDK7CCNHCDK1CDK5
SCHEMBL18078646 0.89 EGFR (0.73) EGFRCDK7CCNHCDK1CDK5
SCHEMBL20289038 0.88 CDK7 (0.73) EGFRCDK7CCNHCDK1CDK5
SCHEMBL18078675 0.86 CDK7 (0.74) EGFRCDK7CCNHCDK1CDK5
SCHEMBL18078641 0.86 EGFR (0.75) EGFRCDK7CCNHCDK1CDK5
SCHEMBL22143288 0.86 CDK7 (0.75) EGFRCDK7CCNHCDK1CDK5
SCHEMBL24900624 0.85 CDK1 (0.62) EGFRCDK7CCNHCDK1CDK5
SCHEMBL30221470 0.85 CDK1 (0.62) EGFRCDK7CCNHCDK1CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200197392-A1 COMPOSITIONS AND METHODS FOR TREATING TUBEROUS SCLEROSIS COMPLEX THE BRIGHAM & WOMEN'S HOSPITAL, INC. (US) 2020-06-25 — — US disclosed
WO-2019035866-A1 COMPOSITIONS AND METHODS FOR TREATING TUBEROUS SCLEROSIS COMPLEX THE BRIGHAM & WOMEN'S HOSPITAL, INC. (US) 2019-02-21 — — WO disclosed
US-20160264552-A1 HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES SYROS PHARMACEUTICALS INC (US) 2016-09-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200197392-A1 COMPOSITIONS AND METHODS FOR TREATING TUBEROUS SCLEROSIS COMPLEX CDK7, CDK17, MTOR EGFR 2279/4885CDK7 1/4885CCNH 16/4885
US-20160264552-A1 HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES CDK7, CDK6, CDK3 EGFR 3410/4885CDK7 1/4885CCNH 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback